TransCode Therapeutics (RNAZ) News Today → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free RNAZ Stock Alerts $0.73 +0.11 (+18.48%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:04 PM | msn.comWhy TransCode Therapeutics (RNAZ) Stock Is Getting HammeredMay 13 at 8:48 AM | investorplace.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?May 13 at 8:30 AM | globenewswire.comTransCode Therapeutics Open Letter to ShareholdersApril 17, 2024 | uk.investing.comFDA clears TransCode's drug trial for advanced tumorsApril 15, 2024 | globenewswire.comTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsApril 4, 2024 | markets.businessinsider.comPromising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode TherapeuticsApril 3, 2024 | globenewswire.comTransCode Therapeutics Reports 2023 Results; Provides Business UpdateMarch 30, 2024 | uk.investing.comTransCode Therapeutics appoints new Chief Medical OfficerMarch 29, 2024 | markets.businessinsider.comTransCode Appoints Daniel Vlock As CMOMarch 28, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 28, 2024 | globenewswire.comTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 11, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | globenewswire.comTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 6, 2024 | globenewswire.comTransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressFebruary 20, 2024 | finance.yahoo.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | globenewswire.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist ImmunotherapeuticFebruary 1, 2024 | uk.investing.comTranscode Therapeutics Inc (RNAZ)January 31, 2024 | finance.yahoo.comNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketJanuary 30, 2024 | benzinga.comLooking Into TransCode Therapeutics's Recent Short InterestJanuary 29, 2024 | markets.businessinsider.comTransCode Collaborates With Debiopharm; Financial Terms Not DisclosedJanuary 29, 2024 | finance.yahoo.comTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerJanuary 22, 2024 | finance.yahoo.comTransCode Therapeutics Announces Closing of $7.25 Million Public OfferingJanuary 19, 2024 | msn.comWhy TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 18, 2024 | marketwatch.comTransCode Therapeutics Shares Slide to 52-Week Low on Planned Public OfferingJanuary 18, 2024 | finance.yahoo.comTransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingJanuary 18, 2024 | marketbeat.comTrading was temporarily halted for "RNAZ" at 01:01 PM with a stated reason of "LULD pause."January 15, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitJanuary 15, 2024 | marketbeat.comTrading was temporarily halted for "RNAZ" at 07:01 PM with a stated reason of "News pending."January 14, 2024 | benzinga.comTransCode Therapeutics Stock (NASDAQ:RNAZ) Dividends: History, Yield and DatesJanuary 12, 2024 | marketwatch.comStocks to Watch: TransCode Therapeutics, Rackspace Technology, Williams-SonomaJanuary 12, 2024 | msn.comTransCode Therapeutics announces retirement of CEOJanuary 12, 2024 | finance.yahoo.comTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEOJanuary 11, 2024 | finance.yahoo.comTransCode Therapeutics Announces 1-for-40 Reverse Stock SplitJanuary 4, 2024 | finance.yahoo.comTransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and ObjectivesDecember 12, 2023 | finance.yahoo.comTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138December 4, 2023 | finance.yahoo.comTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq RulesNovember 14, 2023 | finance.yahoo.comTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business UpdateOctober 31, 2023 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Withdraws Public OfferingOctober 30, 2023 | finance.yahoo.comTransCode Therapeutics Withdraws Public OfferingOctober 27, 2023 | finance.yahoo.comNasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to ConditionsOctober 27, 2023 | investorplace.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?October 26, 2023 | benzinga.comTransCode Therapeutics Announces Public Offering of Common StockOctober 26, 2023 | finance.yahoo.comTransCode Therapeutics Announces Public Offering of Common StockOctober 26, 2023 | benzinga.comTransCode Therapeutics Stock (NASDAQ:RNAZ), Analyst Ratings, Price Targets, PredictionsOctober 26, 2023 | finance.yahoo.comTransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138October 25, 2023 | markets.businessinsider.comPromising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily BodnarOctober 16, 2023 | finance.yahoo.comTransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGASeptember 30, 2023 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Closing of $8.5 Million Public OfferingSeptember 28, 2023 | finance.yahoo.comTransCode Therapeutics Announces Closing of $8.5 Million Public OfferingSeptember 26, 2023 | benzinga.comWhy Transcode Therapeutics (RNAZ) Stock Is Down Nearly 70% Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE BUY ALERT: Move Fast, Musk... (Ad)I recently traveled to Phoenix, Arizona...And based on what I saw out there, I'm prepared to put my reputation on the line. Since 2018, my investment recommendations have averaged 115% per year. But one investment I've just discovered could blow them all away. You won't believe what I saw in Phoenix. RNAZ Media Mentions By Week RNAZ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAZ News Sentiment▼-0.020.57▲Average Medical News Sentiment RNAZ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAZ Articles This Week▼52▲RNAZ Articles Average Week Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Processa Pharmaceuticals News Today Shuttle Pharmaceuticals News Today Tenax Therapeutics News Today Pulmatrix News Today Can-Fite BioPharma News Today Pasithea Therapeutics News Today Universe Pharmaceuticals News Today ASLAN Pharmaceuticals News Today Ainos News Today Hepion Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAZ) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldBiden FINISHED On June 13th?Paradigm PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.